Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04169074 · ClinicalTrials.gov registry record · Phase 2
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04169074 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 7 participants.
The verdict
NCT04169074, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04169074
The ClinicalTrials.gov registry entry for NCT04169074 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT04169074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04169074 about?
NCT04169074 is a clinical study titled "Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)". This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT04169074?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-07-07. Estimated completion is 2025-01-13.
What interventions are being tested in trial NCT04169074?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04169074?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.